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change physician behavior by implementing new protocols and continue to mon-
itor ongoing administrations of multiple CT scans. The study also warrants poten-
tial investigation of similar European hospital databases.
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OBJECTIVES: The economic crisis has led Greece to adopt measures towards re-
ducing public pharmaceutical expenditure. One of the most important key sectors
addressed was that of the market share of generics. The aim of the study was to
evaluate stakeholder’s perceptions of the recently introduced or planned pharma-
ceutical policy reforms regarding generics policy in Greece. METHODS: A qualita-
tive study, using the method of semi-structured interviews was conducted. We
identified 24 decision makers and opinion leaders from public and private organi-
zations, after developing an influence map. In total 17 interviews were conducted,
using an open-ended questions guide. The interviews were tape recorded, tran-
scribed and content analyzed. RESULTS: The majority of stakeholders perceived
the prices of generics as “high” and “non-competitive” and their pricing system as
problematic, also highlighting the lack of incentives for increased use of generics
that results in low penetration in the market. An important issue strongly empha-
sized was the introduction of stricter audit and quality control mechanisms. Re-
garding INN prescribing, stakeholders appeared to be skeptical for both its effec-
tiveness and its viability, as concerns focusing on the maturity of the system, on
the culture and education of the physicians and on the lack of monitoring mecha-
nisms, cannot guarantee its effective implementation. CONCLUSIONS: There is
general agreement that a generics policy in Greece should aim at having low prices
and higher generic penetration in the market, by introducing incentives for all
stakeholders as well as ensuring the quality and safety of generics. The introduc-
tion of INN was not clearly deemed as a measure that can assist to achieve the goal
of containing pharmaceutical expenditure. The pricing system of generics has now
been reformed, leading to lower prices. Further policy measures are needed in the
framework of a comprehensive generics policy in order to increase generics con-
sumption.
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OBJECTIVES: Identify differences of biosimilar uptakes across the EU big five:
France, Italy, Germany, UK, Spain, and USA. METHODS: We identified policies and
biosimilars market shares in volume and value in EU big five: France, Italy, Ger-
many, UK, Spain and USA. We browsed websites of EU and national (when appli-
cable) drug agencies, ministries of health, HTA bodies, payers, manufacturer
unions etc. We completed our research with literature search and grey reports, as
well as Datamonitor reports, IMS data and proprietary pharmavitae database.
RESULTS: Contrary to FDA, EMA has a well defined regulatory path for biosimilars.
However, when the US Patient Protection and Affordable Care Act 2010 enters into
force in 2014, the biosimilars market will be boosted. Today 80% of this market is in
EU. While uptakes in Spain and UK have started to increase, Germany and France
account currently for half of the biosimilars market by value in EU with a 36% and
19% share respectively. In UK, biosimilars have had low penetration, and in Italy
the market is far behind other countries. Other countries with apparently high
sales of biosimilars like Greece are source countries for parallel market. Obviously
there is no overlap between the generics market size and the biosimilars one. The
slow uptake versus generics can be explained by the low discount of biosimilar
price versus branded products and the uncertainty about the clinical effect.
CONCLUSIONS: The lack of regulatory path in USA makes difficult the launch of
biosimilars. However, EU is the experimental field where companies develop their
ability to capture this market. Small molecule generics continue representing the
main source of cost savings in Europe. Biosimilars represent a huge opportunity for
cost saving in the future especially in the USA where the biologic market is leader.
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OBJECTIVES: To examine predictors of drug therapy problems (DTP) among pa-
tients who received a telephonic medication therapy management (MTM)
program. METHODS: Retrospective data was collected from 712 Medicaid patients
who received an initial medication therapy review (MTR) as part of a statewide
telephonic MTM program during an 18-month period. Data was extracted from two
administrative claims files for health care utilization and prescription dispensing
information and one medical record file for MTM program information. For analy-
ses, the main outcome variable was the number of pharmacist-identified DTPs
during the initial MTR. Univariate and multivariate models examined the variables
of age, sex, co-morbid conditions, number of inpatient, outpatient, and emergency
department (ED) visits, number of total, chronic, and narrow therapeutic index
drugs, total medication doses per day, and the number of prescribers and dispens-
ing pharmacies for their relationship with the main outcome. For all medication
and service utilization variables, only data from the three months prior to the MTR
were included. RESULTS: At least one DTP was identified in 61.1% of patients (per
patient mean 22/ 25.) Univariate analyses found that female sex, diagnosis of
hyperlipidemia, number of ED visits, number of total and chronic medications,
total medication doses per day, and the number of pharmacies where patients had
prescriptions filled were significantly (p 0.05) associated with having more DTPs.
In multivariate analyses, female sex, diagnosis of hyperlipidemia, number of ED
visits, and number of total and chronic medications remained as significant pre-
dictors (p0.05) of DTPs. In sensitivity analyses for 10, 20, 30, and 40 or more DTPs
per patient, these variables remained significant predictors in the models except
for number of chronic medications. CONCLUSIONS: Providers and policymakers
planning the implementation of MTM services, particularly for Medicaid patients,
may benefit from considering these findings in defining targeted populations for
service delivery.
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OBJECTIVES: The objective of this paper was to examine the performance of 90
public general hospitals of the Greek National Health System (GNHS) in 2010, rank
hospitals according to their efficiency and identify potentials for input reductions.
Additionally, the aim of the study was to identify best practices regarding procure-
ment policies for pharmaceuticals and other medical goods used by the most effi-
cient hospitals. METHODS: Data Envelopment Analysis (DEA) was used for the
estimation of efficiency scores. The number of beds, doctors, management and
nursing personnel and total hospital expenditures were used as inputs and number
of patient admissions, patient days, outpatient visits and surgical interventions as
outputs. In order to identify best practices regarding the efficient performance of
the leading hospitals, a panel of academic experts and executives of the three top
performing hospitals, was used. RESULTS: The results show that only 31% of Greek
hospitals are efficient, with a mean efficiency score of 85.5%. Among hospitals with
the highest efficiency scores (100%) were two University hospitals and one private-
non profit hospital. All three hospitals managed on average, an 11.6% decrease in
pharmaceutical expenditure and 20.1% in the procurement of orthopaedics-pros-
thetics and other medical goods compared to the previous year. At the same time,
the number of admissions increased on average by 8.1% and the number of surgical
interventions also increased in to hospitals by more than 2%. Regarding the best
practices used, the experts agreed that among the most effective procurement
policies are tendering and renegotiation with a number of suppliers. Additionally,
they all agreed that the introduction of e-procurement decreased pharmaceutical
and other medical goods consumption. CONCLUSIONS: If the GNHS was to elimi-
nate inefficiency it could save up to 208.5 million euro or 10.3 % of the total budget
allocated to public hospitals in 2010.
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OBJECTIVES: In difficult economic periods policymakers implement cost-contai-
ment measures in the specialty care. Therefore hospital managers have to improve
the technical efficiency of operation. In Hungary merger of hospitals were initiated
to take advantage of economies of scale. Our objective was to assess whether the
merger of the Clinical Center of University of Pecs and the Hospital of Baranya
County in 2010 improved the sustainability and technical efficiency of these
institutions. METHODS: Our analysis was based on data from the controlling sys-
tem of these institutions. We compared revenues, costs, number of cases and
performance data before (2009) and after the merger (2011). RESULTS: After the
merger the National Health Insurance Fund Administration (NHIFA) cut the per-
formance volume limit (PVL) of the institution by 11,7%. This resulted in a reduc-
tion of patient volumes and revenues. The number of cases decreased differen-
tially: it fell by 9,2% on those departments that were previously operated parallel by
both institutions, and only by 2,7% on those department that were earlier only
operated by the Clinical Center. The total bed utilization rate also declined by 6,2%.
The management of the Clinical Center could reduce the operational costs by 958
million HUF by decreasing the number of staff and renegotiating supply contracts.
However due to the decreasing PVL the cost/DRG increased from 136’600 to 149’600
HUF/DRG. CONCLUSIONS: The management of the hospitals applied ceteris pari-
bus assumptions when predicting the outcomes of merge prior to the decision.
NHIFA implemented serious cost-containment measures as a consequence of the
economic crisis. Despite of significant reduction in operational costs, the technical
efficiency of the Clinical Center declined. The institution could not properly adapt
to the loss of revenue caused by the PVL reduction after the merger. In difficult
economic period the ceteris paribus assumption has to be supplemented with
scenario analysis.
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OBJECTIVES: However, the number of disabled pensioner under and in normal
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